Akèy › Limfom Difize Gwo Selil B › Texas › Dallas
Etid klinik pou Limfom Difize Gwo Selil B nan Dallas, TX
13 etid pou Limfom Difize Gwo Selil B ap chèche patisipan nan sit nan ak bò kote Dallas (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Ap rekriteFaz 2
- UT Southwestern Medical Center ( Site 0190), Dallas
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Ap rekriteFaz 3
- Texas Oncology - DFW ( Site 8000), Dallas
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Ap rekriteFaz 1
- University of Texas Southwestern, Dallas
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Ap rekriteFaz 1
- Texas Oncology - DFW (Sammons CC), Dallas
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Ap rekriteFaz 2
- Texas Oncology - Dallas Fort Worth, Dallas
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Ap rekriteFaz 1/2
- Baylor University Medical Center, Dallas
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
Ap rekriteEtid obsèvasyon
- UT Southwestern Medical Center, Dallas
DALY II USA/ MB-CART2019.1 for DLBCL
Ap rekriteFaz 2
- UT Southwestern Medical Center, Dallas
Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
Ap rekriteFaz 2
- University of Texas Southwestern Medical Center, Dallas
IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL
Ap rekriteFaz 1/2
- University of Texas Southwestern Medical Center, Dallas
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
Ap rekriteFaz 1/2
- University of Texas(UT) Southwestern-Children's Medical Center, Dallas
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Ap rekriteFaz 1
- University of Texas Southwestern Medical Center, Dallas
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
Ap rekriteFaz 1/2
- UT Southwestern Medical Center, Dallas
Etid Limfom Difize Gwo Selil B nan lòt vil
- New York City, NY21 etid
- Baldwin Park, CA19 etid
- Chicago, IL18 etid
- Los Angeles, CA17 etid
- Houston, TX17 etid
- Boston, MA16 etid
- Milwaukee, WI16 etid
- Portland, OR15 etid
- Philadelphia, PA15 etid
- Durham, NC14 etid
- Nashville, TN14 etid
- Seattle, WA12 etid
Lòt etid nan Dallas
- Kansè nan tete54 etid
- Kansè Poumon ki pa ti selil52 etid
- Ensifizyans kadyak42 etid
- Kansè Metastatik42 etid
- Kansè (tout kalite)38 etid
- Kansè pwostat36 etid
- Kansè kolorektal33 etid
- Obèsite31 etid
- Kansè ovè28 etid
- Kansè vejik27 etid
- Kansè poumon27 etid
- Kansè Endomèt25 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.